MX2010001390A - Métodos para el tratamiento de dependencia. - Google Patents

Métodos para el tratamiento de dependencia.

Info

Publication number
MX2010001390A
MX2010001390A MX2010001390A MX2010001390A MX2010001390A MX 2010001390 A MX2010001390 A MX 2010001390A MX 2010001390 A MX2010001390 A MX 2010001390A MX 2010001390 A MX2010001390 A MX 2010001390A MX 2010001390 A MX2010001390 A MX 2010001390A
Authority
MX
Mexico
Prior art keywords
methods
treating
dependence
substance
patients
Prior art date
Application number
MX2010001390A
Other languages
English (en)
Spanish (es)
Inventor
Tom Woiwode
Mark Moran
Lesley Pickford
Original Assignee
Synosia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics Inc filed Critical Synosia Therapeutics Inc
Publication of MX2010001390A publication Critical patent/MX2010001390A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2010001390A 2007-08-06 2008-08-06 Métodos para el tratamiento de dependencia. MX2010001390A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93532307P 2007-08-06 2007-08-06
US95655507P 2007-08-17 2007-08-17
US96059107P 2007-10-04 2007-10-04
PCT/US2008/072357 WO2009021055A1 (en) 2007-08-06 2008-08-06 Methods for treating dependence

Publications (1)

Publication Number Publication Date
MX2010001390A true MX2010001390A (es) 2010-08-02

Family

ID=40341713

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2010001390A MX2010001390A (es) 2007-08-06 2008-08-06 Métodos para el tratamiento de dependencia.
MX2015009454A MX357542B (es) 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia.
MX2018008628A MX391921B (es) 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia
MX2022001510A MX2022001510A (es) 2007-08-06 2010-02-04 Nepicastat para usarse en el tratamiento de dependencia.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2015009454A MX357542B (es) 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia.
MX2018008628A MX391921B (es) 2007-08-06 2008-08-06 Nepicastat para usarse en el tratamiento de dependencia
MX2022001510A MX2022001510A (es) 2007-08-06 2010-02-04 Nepicastat para usarse en el tratamiento de dependencia.

Country Status (16)

Country Link
US (3) US20090041800A1 (cg-RX-API-DMAC7.html)
EP (2) EP3251670A1 (cg-RX-API-DMAC7.html)
JP (5) JP2010535801A (cg-RX-API-DMAC7.html)
CN (2) CN106983747A (cg-RX-API-DMAC7.html)
AU (1) AU2008283903B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0815089A2 (cg-RX-API-DMAC7.html)
CA (1) CA2695372C (cg-RX-API-DMAC7.html)
CO (1) CO6260015A2 (cg-RX-API-DMAC7.html)
ES (1) ES2638190T3 (cg-RX-API-DMAC7.html)
IL (1) IL257418A (cg-RX-API-DMAC7.html)
MX (4) MX2010001390A (cg-RX-API-DMAC7.html)
NZ (1) NZ583192A (cg-RX-API-DMAC7.html)
PH (1) PH12015502210A1 (cg-RX-API-DMAC7.html)
RU (1) RU2491067C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201705968RA (cg-RX-API-DMAC7.html)
WO (1) WO2009021055A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0815089A2 (pt) 2007-08-06 2014-09-30 Synosia Therapeutics Inc Métodos para tratar um paciente que sofre de ou suscetível a pelo menos um sintoma de abuso de, dependência sobre, ou retirada de pelo menos uma substância, para tratar pelo menos uma fase de dependência de substância sobre pelo menos uma substância em um paciente, e para tratar pelo menos uma fase de dependência à cocaína em um paciente.
WO2010124089A2 (en) * 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
US9804149B2 (en) * 2012-10-10 2017-10-31 Bio-Rad Laboratories, Inc. Patient-based results display
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
US20170235908A1 (en) * 2015-11-15 2017-08-17 Oriah Behaviorial Health, Inc. Systems and Methods for Managing and Treating Substance Abuse Addiction
WO2019038756A1 (en) 2017-08-20 2019-02-28 Solubest Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN108066355A (zh) * 2017-12-28 2018-05-25 宁夏恩多芬科技有限公司 Nitrous Oxide作为治疗神经官能症的用途
FR3093419B1 (fr) * 2019-03-08 2021-06-18 Univ Grenoble Alpes Composition et procédé associé de mesure de l’observance thérapeutique
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
PT3873883T (pt) * 2019-11-07 2023-03-24 Small Pharma Ltd Método de síntese
US11806320B2 (en) * 2020-02-19 2023-11-07 Endo Ventures Limited Isoproterenol compositions and methods
IL312785A (en) 2020-05-19 2024-07-01 Cybin Irl Ltd Denatured Tryptamine Derivatives and Methods of Use
IL300689A (en) * 2020-08-17 2023-04-01 Univ Columbia Use of neuromelanin-sensitive MRI as a biomarker of dopamine function
JP7753359B2 (ja) * 2020-10-24 2025-10-14 ユニヴェルシテートスピタル バーゼル ヒト血漿中のリゼルギン酸ジエチルアミド（ｌｓｄ）及び２，３－ジヒドロ－３－ヒドロキシ－２－オキソリセルギド（ｏ－ｈ－ｌｓｄ）を定量化するための方法
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112690771B (zh) * 2020-12-09 2022-05-24 华南理工大学 一种利用线性回归模型的人脸视频心率检测方法
US12079960B2 (en) 2021-03-11 2024-09-03 Terran Biosciences Inc. Systems, devices, and methods for harmonization of imaging datasets including biomarkers
CN113017632B (zh) * 2021-03-17 2022-11-11 陈思 一种智慧校园心理咨询辅助方法及系统
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
AU2023340289A1 (en) 2022-09-16 2025-03-13 Asieris Pharmaceuticals (Shanghai) Co., Ltd. Polymorphic form of nepicastat acid addition salt, preparation method therefor and use thereof
WO2024178082A2 (en) * 2023-02-22 2024-08-29 Freedom Biosciences, Inc. Composition of opioid receptor modulator and mdma for use thereof
CN120754106B (zh) * 2025-09-02 2025-12-09 合肥工业大学 化合物sch23390在制备治疗铅中毒药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500411A (ja) * 1987-10-07 1991-01-31 マトリックス　テクノロジーズ　インコーポレーテッド コカイン中毒の処置および治療薬
US5593367A (en) * 1995-08-18 1997-01-14 Deere & Company Switchable ignition and starter control system
EP0883609A1 (en) * 1996-02-23 1998-12-16 Pharmeco Laboratories, Inc. Selective d1 dopamine receptor agonists and partial agonists/antagonists
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
DE60214527T2 (de) * 2001-01-17 2007-04-05 Hythiam, Inc., Los Angeles Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
US20030040015A1 (en) * 2001-03-07 2003-02-27 Kwang-Soo Kim Methods and reagents for identifying compounds and mutations that modulate dopamine beta-hydroxylase activity
SE0104388D0 (sv) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
EP1603595B1 (en) * 2003-02-27 2010-11-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
RU2252756C1 (ru) * 2003-12-23 2005-05-27 Хохлов Александр Петрович Препарат против алкоголизма и наркомании, способ получения такого препарата
AU2008229203B2 (en) * 2007-03-16 2014-05-29 Emory University Methods and compositions for treatment of drug addiction
MX2010000938A (es) * 2007-07-23 2010-07-01 Synosia Therapeutics Inc Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder
AU2008279091A1 (en) * 2007-07-23 2009-01-29 Biotie Therapies, Inc Treatment of post-traumatic stress disorder
BRPI0815089A2 (pt) 2007-08-06 2014-09-30 Synosia Therapeutics Inc Métodos para tratar um paciente que sofre de ou suscetível a pelo menos um sintoma de abuso de, dependência sobre, ou retirada de pelo menos uma substância, para tratar pelo menos uma fase de dependência de substância sobre pelo menos uma substância em um paciente, e para tratar pelo menos uma fase de dependência à cocaína em um paciente.
EP2218804A4 (en) 2007-11-26 2011-08-24 Bridgestone Corp GALVANIZATION BATH FROM COPPER-ZINC ALLOY AND PLATING PROCESS WITH GALVANIZING BATH FROM COPPER-ZINC ALLOY

Also Published As

Publication number Publication date
AU2008283903B2 (en) 2014-01-16
US20090041800A1 (en) 2009-02-12
CO6260015A2 (es) 2011-03-22
RU2010108249A (ru) 2011-09-20
MX357542B (es) 2018-07-13
CA2695372C (en) 2013-01-22
EP3251670A1 (en) 2017-12-06
JP2018154645A (ja) 2018-10-04
SG183696A1 (en) 2012-09-27
CA2695372A1 (en) 2009-02-12
CN101815438A (zh) 2010-08-25
US20200383951A1 (en) 2020-12-10
MX391921B (es) 2025-03-21
US10561638B2 (en) 2020-02-18
AU2008283903A1 (en) 2009-02-12
EP2182804B1 (en) 2017-05-24
CN106983747A (zh) 2017-07-28
ES2638190T3 (es) 2017-10-19
SG10201705968RA (en) 2017-08-30
JP2014148551A (ja) 2014-08-21
RU2491067C2 (ru) 2013-08-27
JP2020114883A (ja) 2020-07-30
JP2016210798A (ja) 2016-12-15
JP2010535801A (ja) 2010-11-25
BRPI0815089A2 (pt) 2014-09-30
NZ583192A (en) 2012-06-29
EP2182804A4 (en) 2010-12-22
PH12015502210A1 (en) 2017-04-10
IL257418A (en) 2018-04-30
US20140099336A1 (en) 2014-04-10
MX2022001510A (es) 2022-08-11
WO2009021055A1 (en) 2009-02-12
EP2182804A1 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
MX2010001390A (es) Métodos para el tratamiento de dependencia.
WO2010124089A3 (en) Nepicastat for treating dependence
EP2116952A4 (en) INFORMATION PROCESSOR WITH LOCKING FUNCTION, LOCKING (RELEASE) METHOD FOR AN INFORMATION PROCESSOR AND PROGRAM THEREFOR
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
MX2010006823A (es) Metodos para el tratamiento de la gota.
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP2203169A4 (en) GLYCEMIC INSPECTION, DIABETES TREATMENT, AND OTHER TREATMENTS WITH ACETYLCHOLINESTERASE INHIBITORS
MX337586B (es) Anticuerpos anti-interleucina-1beta para usarse en el tratamiento de condiciones relacionadas con interleucina-1beta.
ZA201000173B (en) Method for treating an at least partially metallised textile, treated textile and the use thereof
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
IL207792A0 (en) Methods, dosage forms, and kits for administering ziprasidone without food
WO2010052312A8 (fr) Medicament ou composition dermatologique comprenant un extrait peptidique d'avocat destine au traitement et a la prevention du prurit
BRPI0819195A2 (pt) métodos para tratar escleroderma em um paciente em necessidade de tal tratamento e para aliviar um ou mais dos sintomas associados com escleroderma em um paciente em necessidade de tal tratamento.
EP2371340A4 (en) DRUG-RELATED DRUG-RELATED DRUG REDUCTION INSTRUMENT, METHOD OF USE THEREOF, AND METHOD OF TREATING ADDICTION-RELATIVE DRUGS DEPENDENCE
MX2009012957A (es) Metodo para tratar diabetes.
SG196770A1 (en) Method for treating macular degeneration
WO2010056472A3 (en) Compositions and methods of use for soluble thrombomodulin variants
UA42465U (ru) Способ профилактики лучевой болезни в эксперименте
UA36369U (ru) Способ лечения артериальной гипертензии на санаторно-курортном этапе
UA34805U (ru) Способ профилактики рецидивов параноидной шизофрении
UA27462U (en) Method for treating metabolic disorders in patients with arterial hypertension taking into account genotype
Lee A Study on the Problems and Improvements of BTL Project Process
IL196633A0 (en) An anaerobic digester and a method for treating sludge in the digester
Jeon et al. Study on establishing 2009 System Restoration Plan
UA34799U (ru) Способ профилактики обострений параноидной шизофрении

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIOTIE THERAPIES, INC.*

FC Refusal